These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34179738)

  • 1. Embedding assessment of liver fibrosis into routine diabetic review in primary care.
    Mansour D; Grapes A; Herscovitz M; Cassidy P; Vernazza J; Broad A; Anstee QM; McPherson S
    JHEP Rep; 2021 Aug; 3(4):100293. PubMed ID: 34179738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
    Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
    JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence of Advanced Liver Fibrosis Among Patients With Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia.
    Lee XH; Nor LM; Ang CS; Yeow TP; Lim SL
    J ASEAN Fed Endocr Soc; 2023; 38(1):52-61. PubMed ID: 37252406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
    Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
    Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease.
    Alam MS; Kamrul-Hasan ABM; Kalam ST; Rahman SMM; Hoque MI; Islam MB; Paul AK
    Diabetes Metab Syndr Obes; 2021; 14():3089-3096. PubMed ID: 34262313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease.
    Seki K; Shima T; Oya H; Mitsumoto Y; Mizuno M; Okanoue T
    Hepatol Res; 2017 Aug; 47(9):882-889. PubMed ID: 27753194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
    JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
    Vieira Barbosa J; Lai M
    Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
    Chhabra S; Singh SP; Singh A; Mehta V; Kaur A; Bansal N; Sood A
    J Clin Exp Hepatol; 2022; 12(2):409-416. PubMed ID: 35535092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
    McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
    BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case-finding strategies in non-alcoholic fatty liver disease.
    Boursier J; Tsochatzis EA
    JHEP Rep; 2021 Apr; 3(2):100219. PubMed ID: 33659890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.